Five important facts about heart-failure medications

An update from the European Society of Cardiology on standards and new drugs in the treatment of heart failure management states:

  1. Neurohormonal antagonists, such as ACEIs and beta-blockers, have been shown to improve survival in patients with heart failure with reduced ejection fraction (HFrEF), and are recommended unless contraindicated or not tolerated.
  2. A new compound (LCZ696) that combines the moieties of an ARB (valsartan) and a neprilysin inhibitor (sacubitril) has recently been shown to be superior to an ACEI (enalapril) in reducing the risk of death and of hospitalisation for HF. It is